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ABSTRACT OF THESIS

CLINICAL OUTCOMES ASSOCIATED WITH TIME TO ANTIMICROBIAL
THERAPY CHANGE FROM VANCOMYCIN TO DAPTOMYCIN IN
STAPHYLOCOCCAL BACTEREMIA
Background: Staphylococcus aureus is an aerobic, Gram positive commensal organism
that is capable of causing a wide spectrum of disease. This study contributes to
previously published literature regarding daptomycin versus vancomycin use in S. aureus
bacteremia (SAB).
Methods: Adult patients admitted between 2010 and 2014, billed for ICD-9 code V09.0,
038.11, 038.12, 041.11, or 041.12, and received vancomycin and daptomycin were
included in this retrospective analysis. Patients were stratified by time to change in
antibiotics from vancomycin to daptomycin to the early switch (1-3 days), intermediate
switch (4-7 days), or late switch (8 days or later) group. The primary outcome was
treatment failure defined as 30-day recurrence, 60-day all-cause mortality, and 90-day
all-cause readmission.
Results: 193 patients were enrolled in the final cohort. The overall treatment failure rate
was 18% with no differences between early switch, intermediate switch, and late switch
(P=0.72) groups. Independent predictors of treatment success were length of stay
(OR=1.035) and time to positive culture (OR=0.961).
Conclusions: Results of this study did not demonstrate a difference in treatment failure
based on time to switch from vancomycin to daptomycin. Future research should focus
on optimizing use of vancomycin and daptomycin and medical management of SAB.
KEYWORDS: Staphylococcus aureus, vancomycin, daptomycin, outcomes research
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CHAPTER ONE: BACKGROUND

Staphylococcus aureus is an aerobic, Gram positive bacterium naturally found as a
commensal organism on the skin of humans. It especially resides in the nares and can be
a facultative anaerobic organism.1 Once it breaches the barrier of the skin, S. aureus can
become an opportunistic pathogen capable of causing a wide spectrum of disease in
humans including skin and soft tissue infections (SSTIs), osteoarticular infections,
pleuropulmonary disease, food poisoning and gastrointestinal upset, meningitis, and
bloodstream infection (BSI) and infective endocarditis (IE).2,3 Surface adhesins on the
bacteria mediate adherence to and colonization of end target tissues.1,2. Mobile genetic
elements are responsible for development of antibiotic resistance mechanisms that have
allowed S. aureus infections to persist during the antibiotic era. Key mobile genetic
elements that will be discussed include bla genes which are responsible for betalactamase production, and the staphylococcal cassette chromosome (SCC) which is
responsible for methicillin resistance.2,4

In 1940, penicillin became widely available and revolutionized management of infectious
diseases. This prototypical beta-lactam has bactericidal activity by binding to penicillinbinding protein in the cell wall of Gram-positive organisms and inhibiting peptidoglycan
cross-linking, thus disrupting cell wall synthesis.5 By 1942, S. aureus demonstrated
resistance to penicillin through production of a beta-lactamase enzyme that is capable of
hydrolyzing the beta-lactam ring central to penicillin and inactivating the compound.2,6
Now, more than 85% of S. aureus isolates produce this beta-lactamase.7 There are three
1

key bla genes that confer beta-lactamase production: blaZ, blaR, and blaI.2,4 They are
encoded on transposons or plasmids and are inducible. Plasmids are auto-replicating
DNA molecules that exist separate from the chromosome. blaR and blaI are regulator
genes that also be found on the SCCmec that will be discussed in more detail.2

In 1959, beta-lactam antibiotics that remained stable against this beta-lactamase were
developed with methicillin being the prototypical agent in this antistaphylococcal class.
In 1961, methicillin-resistant isolates of S. aureus began to emerge.8 Methicillin
resistance is caused by alteration of the beta-lactam binding site at penicillin binding
protein (PBP) 2a which has decreased affinity for beta-lactam antibiotics. This altered
PBP is encoded by the mecA gene SCCmec.2,4 The SCC is a large fragment of DNA that
is always inserted into the S. aureus chromosome. There are other SCC groups that do
not confer methicillin resistance, so these are referred to as non-SCCmec groups. All
methicillin-resistant S. aureus (MRSA) contain one type out of eight SCCmec types.
These different types are responsible for community-acquired (CA-MRSA) versus
hospital-acquired (HA-MRSA), which cause distinct infectious syndromes in different
patient populations.4

Patients who have come into contact with the healthcare system are at risk for HAMRSA. Risk factors for HA-MRSA include prolonged hospitalization, stay in the
intensive care unit (ICU), prolonged antimicrobial therapy, surgical procedures, and close
proximity to a patient in the hospital who is infected or colonized with MRSA. HAMRSA is often multidrug resistant and causes pneumonias and BSIs.2,9,10 Roughly 40-
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50% of hospital-acquired S. aureus isolates are methicillin-resistant.9 CA-MRSA is
acquired from coming into direct contact with the organism through skin-to-skin contact
with infected or colonized individuals or contaminated fomites. While some of these
individuals may have come into contact with the healthcare system, there have been
reports of community-acquired SSTIs in correctional facilities, military personnel, daycare centers, men-who-have-sex-with-men, and athletes.11,12 CA-MRSA usually causes
SSTIs, and can be responsible for necrotizing pneumonia and osteomyelitis.2,11 CAMRSA most often contains SCCmec type IV which also carries other virulence factors.2,4
CA-MRSA is resistant to beta-lactam antibiotics, but the other Gram positive-active
agents – which are discussed later – retain much activity against CA-MRSA.11 From a
predominantly community-acquired S. aureus cohort, 42% of isolates from the
bloodstream and 58% of isolates from wounds or abscesses were methicillin-resistant.13

Because it is a commensal organism that has the potential to cause opportunistic
infections, incidence of S. aureus infection is high. A study using administrative data
from The Surveillance Network (TSN) Database-USA estimated the rate of S. aureusrelated hospitalizations at 17.68 per 1,000 hospitalizations in 2009.14 A study of health
plan beneficiaries demonstrated the rate of S. aureus SSTIs to be 142.8 per 100,000 years
and the rate of S. aureus bacteremia (SAB) to be 4.7 per 100,000 patient years.13 One
population based study out of Minnesota estimates an annual incidence of S. aureus
bacteremia (SAB) of 38.2 per 100,000 person-years over the period between 1998 and
2005.15 There were no differences in incidence over the seven-year period. However, the
incidence of MRSA bacteremia increased significantly in this cohort over the studied
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time period from 4.6 per 100,000 person years in 1998 to 10.8 per 100,000 person years
in 2005. The authors of this study attributed the increased trend in MRSA to increases in
incidence of HA-MRSA, however both CA-MRSA and HA-MRSA are highly incident.
The data from the TSN study estimated a rate of 11.74 per 1,000 hospitalizations for
MRSA.14 Overall rate of CA-MRSA was 45% while HA-MRSA was 55%. BSI due to
MRSA was responsible for 1.59 per 1,000 hospitalizations; 64% were HA-MRSA and
36% were CA-MRSA. Klevens et al. studied 18 months of data on MRSA reported to
the CDC’s Emerging Infections Program/Active Bacterial Core surveillance program.16
Eighty-five percent of MRSA infections were hospital-acquired and 13.7% were
community-acquired. BSI (75%), pneumonia (13.3%), and cellulitis (9.7%) were the
most common infectious syndromes in this cohort.16

S. aureus is also a prominent cause of nosocomial infections. In a study of healthcareassociated infections reported to the Centers of Disease Control and Prevention National
Healthcare Safety Network for 2009-2010, S. aureus was responsible for 15% of
healthcare-associated infections, causing over 12,000 infections.9 It was the leading
causative pathogen for ventilator associated pneumonia and surgical site infections.9 In
the cohort of 8972 cases of invasive MRSA reported by Klevens et al. above, 26.6% were
hospital-onset infections.16 Risk factors for hospital-onset MRSA include previous
hospitalization, history of surgery, long-term care residence, and previous MRSA
infection or colonization.16

4

Mortality from S. aureus bacteremia is considerable. Overall 30-day mortality rate for is
estimated at 20% with an attributable mortality rate of 13%, while mortality after oneyear is as high as 62%.17,18 The mortality rate for invasive MRSA infection is estimated at
6.3 per 100,000 patients with higher mortality in persons 65 years and older, African
Americans, and males.16 Multivariate analysis of 1600 episodes of SAB from a
retrospective database identified risk factors of mortality to include advanced age, female
gender, pneumonia or unknown source of infection, dementia, Charlson score, shock at
onset, and arrival to hospital from an institution.18

Risk factors for S. aureus infection include immunocompromised state, diabetes,
substance abuse, and age.2,14,19 Young persons under the age of 20 years overall had
lower hospitalization rates for MRSA than older patients.14 One risk factor that largely
contributes to risk is presence of an intravascular catheter used for dialysis. A study
utilizing 2008 data from the CDC’s Emerging Infections Program/Active Bacterial Core
surveillance system estimated the rate of healthcare-associated, community-onset MRSA
bloodstream infections at 404 cases per 10,000 person-years among patients who
received dialysis within one year compared to 1.62 cases per 10,000 person-years in all
patients included in the database.20 Intravenous drug users (IVDUs) are at increased risk
for S. aureus infections due to increased prevalence of nasal colonization, use of
contaminated drugs and paraphernalia, and close personal contact within the drug use
environment.21,22 One incidence study conducted in Detroit, MI, showed that S. aureus
was the causative pathogen in 57% of infections in a cohort of IVDUs with 42% of those
S. aureus isolates being resistant to methicillin.23
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Given the high incidence of S. aureus infection and high mortality rate, maintaining an
effective armamentarium of antistaphylococcal antibiotics is paramount to preventing
these rates from increasing. Cell-wall active and rapidly bactericidal agents such as betalactams remain the drug of choice against S. aureus.24 Due to the previously described
resistance to beta-lactams, other agents with different mechanisms of action have been
developed. The virulent and adaptable S. aureus has developed resistance to all of them.
Presence of the erm gene confers resistance to macrolides, lincosamides, and
streptogrammin B through alteration of the ribosomal target site on S. aureus.4
Macrolides and sreptogrammins are also susceptible to drug efflux if the msrA gene is
present.4 Resistance to the protein synthesis inhibitor linezolid occurs in the presence of
the cfr gene. This target site-modifying gene confers cross-resistance to chloramphenicol
and clindamycin.2,4 S. aureus develops resistance to fluoroquinolones thanks to selective
pressure when this Gram-positive bacterium is introduced to subtherapeutic
concentrations from doses used to treat a concomitant Gram-negative infection. S. aureus
develops mutations at the target enzymes in the DNA synthesis process that are inhibited
by fluoroquinolones.25 The folate antagonist combination trimethoprim/sulfamethoxazole
(TMP/SMX) becomes ineffective against S. aureus when the organism upregulates
production of the sulfonamide target p-aminobenzoic acid or decreases the binding
affinity for trimethoprim to dihydrofolate reductase.25

Once the mutated PBP-2a was elucidated as the cause of methicillin resistance in S.
aureus, this became the target for new beta-lactam development. In 2010, ceftaroline
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fosamil was approved for the treatment of SSTIs and community-acquired pneumonia.2628

This is the first widely available beta lactam to target the mutation in MRSA,

developed almost 50 years after the PBP mutation was discovered. Yet its clinical
applications are limited. Its use in clinical practice is often as a second or third line agent
for MRSA bacteremia, sometimes in combination with another agent.29-31 Data on
ceftaroline in bacteremia is limited to observational studies and registry databases.30,32
Ceftaroline binds with high affinity to the mutated PBP-2a in MRSA and thus requires a
lower minimum inhibitory concentration (MIC) for clinical success.33 However, resistant
isolates have already emerged during its short period of clinical use.34

Vancomycin was first approved in 1958 for treatment of penicillin-resistant S. aureus, but
after the approval of antistaphylococcal beta-lactams, it became a second line agent.35 It
became a first line agent in the 1980s as MRSA began to emerge and has been widely
used since that time.36 Sorrell et al. described vancomycin for the treatment of MRSA
bacteremia in 10 patients and saw no differences in mortality or relapse compared to
patients with MSSA who received a beta-lactam.37 Levine et al. described a cohort of 23
patients with IE caused by CA-MRSA who were treated with vancomycin or a
combination of antibiotics including vancomycin and surgery.38 Sixty-one percent of
patients were cured. It exerts its activity by binding to D-alanyl-D-alanine terminal
peptide of the peptidoglycan precursors, thus preventing cross-linking in the bacterial cell
wall.39 Compared to beta-lactam agents, vancomycin is slowly bactericidal with a median
time to resolution of positive blood cultures of 9 days.40 Vancomycin requires
pharmacokinetic monitoring to ensure both therapeutic efficacy and to monitor patient
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safety.41,42 It is considered a time-dependent killer where optimizing the duration of time
that serum concentrations are at a therapeutic level increases antimicrobial effect. When
examining a concentration versus time curve, the pharmacodynamic parameter to
optimize is a ratio of area-under-the-curve (AUC) to MIC with most studies supporting
an optimal AUC/MIC ratio of 400.43,44 (see Fig. 1.1)

Figure 1.1: Pharmacokinetic and pharmacodynamic illustration of vancomycin.
Concentration (mg/L) is along y-axis and time in hours is along the x-axis. AUC24=area
under the curve over 24 hours (mg/L). MIC=minimum inhibitory concentration
(mg/L).45,46

Unlike other agents that have been developed to combat S. aureus, vancomycin has
largely retained its activity over this period of time. In the last 15 years, only 14 isolates
of vancomycin-resistant strains of S. aureus have been identified globally, with the 14th
being confirmed in 2015.47 Vancomycin resistance is mediated by the plasmid-mediated
vanA gene, which causes an amino acid substitution from the D-alanyl-D-alanine target
site to D-alanyl-D-lactate, preventing vancomycin binding.48 S. aureus acquired this
resistance mechanism through horizontal transmission from Enterococcus, an organism
with which vancomycin resistance is more common.48,49
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Importantly, a more common clinical scenario is S. aureus strains that are intermediately
sensitive to vancomycin. This occurs due to changes in the bacterial cell wall leading to
increased cell wall thickness and overproduction of D-alanyl-D-alanine target site. This
causes vancomycin to become effectively sequestered in the cell wall of the bacteria and
ultimately ineffective.48,50 One phenomenon that is increasing in prevalence is
heterogeneous vancomycin intermediate S. aureus (hVISA) where vancomycin-resistant
subpopulations exist among predominantly susceptible strains, resulting in increased
MICs and failure of vancomycin therapy.50 Prevalence of hVISA was estimated at 1.2%
from a 2011 study of MRSA isolates.51 Risk factors for developing hVISA include
previous vancomycin exposure, high inoculum infections, persistent bacteremia, and
subtherapeutic vancomycin serum concentrations.52-54 HVISA may preclude VISA with
repeated vancomycin exposure exerting selective pressure favoring the subpopulations
with higher MICs.55,56 Previous vancomycin exposure and subtherapeutic vancomycin
concentrations may play a role in decreased susceptibility with other agents, as will be
discussed in a review of daptomycin.

HVISA is speculated to play a role in therapy failure of vancomycin against S. aureus
when the MIC is at the upper end of the susceptibility range, as reported in multiple
studies.57-60 This led to the 2006 decision by the Clinical Laboratory and Standards
Institute to change the vancomycin breakpoints for S. aureus so that an MIC <2 mg/L
was considered susceptible, 4-8 mg/L is considered intermediate, and MIC >16 mg/L is
considered resistant.54 Additionally, multiple centers reported an overall increase in the
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vancomycin MICs of the S. aureus isolates they were encountering clinically.61-64 This
phenomenon is referred to as the MIC creep. A large study using isolates from
international surveillance data from multiple sites of infection was not able to corroborate
the occurrence of the MIC creep, however individual centers’ epidemiological and
clinical factors and susceptibility testing procedures must be considered.65,66

With the 2006 changes in vancomycin breakpoints, the accuracy of the different
susceptibility testing procedures must be considered in determining the impact of this
vancomycin MIC creep. The gold-standard method for determining MIC is broth
microdilution (BMD).67 However, this labor intensive and time consuming methodology
is prohibitive to most clinical microbiology labs. As a result, various automated BMD
testing methods are available. Compared to standard BMD-identified MIC, manual
epsilometer testing (E-testing) and the automated methods may underestimate or
overestimate the true MIC.68-70 This is especially problematic when vancomycin MICs
are closer to 2 mg/L. Rybak and colleagues showed 80% agreement between E-testing
and BMD when the vancomycin MIC equals 2 mg/L while the automated testing
methods ranged from 20%-92% agreement.68 Bland and colleagues showed that 87% of
MRSA isolates had higher vancomycin MICs as determined by E-test than determined by
the automated method.69 Hsu and colleagues looked at vancomycin MIC reporting and
clinical outcomes in MRSA infections.70 In their cohort of patients with MRSA
infections, 17 of 21 patients who failed vancomycin therapy had MICs as determined by
E-testing >1 mg/L. The agreement between other susceptibility testing methods and Etesting when the MIC >1 mg/L ranged from 9%-80%. The study authors saw more
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vancomycin failures at a higher MIC, and E-testing was the most accurate way to
determine MIC with a positive predictive value of 89%.70 Some centers have moved
toward E-testing bloodstream isolates of MRSA for a more accurate estimation of
vancomycin MIC. However, E-testing tends to be conservative and is interpreted
subjectively by microbiology laboratory personnel.

In attempts to answer the question regarding clinical implications of vancomycin MICs at
the upper limit of susceptibility in S. aureus infections, multiple meta-analyses have been
conducted. Three of these meta-analyses concluded that there in an increased risk of
mortality and treatment failure with high, but susceptible vancomycin MICs against S.
aureus.71-73 However, these meta-analyses are limited by heterogeneous definitions of
treatment failure among included studies, different antimicrobial susceptibility testing
methods, and multiple sites of infection. In the prominent meta-analysis by van Hal and
colleagues the authors stated that their findings were driven by BSIs with vancomycin
MIC >2 mg/L by E-test.72 A more recent meta-analysis conducted by Kalil and
colleagues attempted to specifically examine the driver of treatment failure as defined by
van Hal.74 Their meta-analysis included only S. aureus BSIs where the susceptibility was
tested by broth microdilution or E-test and examined all-cause mortality as a primary
outcome. Analysis did not find an increased absolute risk of mortality when the
vancomycin MIC was >1.5 mg/L. The findings by Kalil and colleagues support current
Infectious Diseases Society of America (IDSA) recommendations against using
vancomycin MIC only to drive therapy decisions and instead use clinical assessment for
management of patients with MRSA bacteremia.75
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One rationale for treatment failure at these MICs includes limited ability to reach
pharmacodynamic targets for optimal bactericidal activity using safe medication doses.
As previously mentioned, the pharmacodynamic target for vancomycin therapy is an
AUC/MIC ratio of 400. Patel and colleagues performed Monte Carlo simulations to
determine both the probability of achieving this pharmacodynamic target at various
vancomycin MICs and the probability of nephrotoxicity at various vancomycin dosing
regimens.76 They found that in MRSA infections with vancomycin MIC of 2 mg/L, in
order to achieve AUC/MIC > 400 80% of the time, one must employ a vancomycin
dosing regimen of 2000mg every 12 hours. However, this dosing regimen was associated
with a 14% chance of nephrotoxicity in non-ICU patients and a 34% chance of
nephrotoxicity in ICU patients. The scenario in which higher doses are required to
achieve therapeutic efficacy must be balanced with minimizing adverse events of
vancomycin therapy.

Though vancomycin has remained efficacious over time, the aforementioned safety and
monitoring limitations led clinicians to develop daptomycin, which is not associated with
nephrotoxicity and requires less monitoring. Daptomycin carries indications for SSTI and
BSI due to S. aureus.77,78 It has a faster bactericidal mechanism of action and, is
administered once daily.79 Initially developed in 1986, clinical trials were halted due to
high occurrence of myalgias and creatine kinase (CK) elevations seen when the drug was
administered multiple times per day.79,80 A new investor and carefully designed safety
trials resurrected daptomycin and in 2003 it was approved by the FDA for SSTI.77 It
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works by forming a cationic complex with calcium and binding to bacterial membranes,
causing rapid depolarization of membrane potential.81

Daptomycin is approved for the treatment of SAB and right-sided IE at a dose of 6 mg
per kilogram (kg), however higher doses have been studied. In the randomized controlled
trial that garnered its approval, daptomycin 6 mg/kg per day was compared to
vancomycin for clinical success at the end of 42 days of therapy. There was no difference
between treatment groups with an absolute difference in success rates of 3.4% (95% CI 8.9-15.7).78 In utilizing the concentration-dependent pharmacodynamics of daptomycin,
higher doses have shown good rates of success and low rates of adverse effects. Kullar et
al. studied daptomycin dosed 8-10 mg/kg in 250 patients with Gram positive infections
and observed an 83.6% clinical success rate.82 Adverse effects in this cohort were rare
with 1.2% of patients experiencing adverse effects and only one patient requiring dose
reduction due to CK elevations. A study of 94 registrants from the post-marketing
Cubicin Outcome Registry Experience database who received daptomycin 8 mg/kg for
Gram positive infections demonstrated an 89% cure rate in clinically evaluable
registrants.83 Adverse effects related to daptomycin occurred in 6.4% of patients
including CK elevations occurring in 3.2% of patients, however, these were all deemed
not clinically relevant. High-dose daptomycin is efficacious without increased rates of
adverse events, and high doses are often utilized in clinical practice.

Since the study by Fowler and colleagues that secure its indication for bacteremia, no
clinical trials have demonstrated daptomycin’s superiority to vancomycin. However,

13

some single center, retrospective studies indicate that it may be superior in certain clinical
situations. One study by Moore and colleagues examined patients with S. aureus who
were changed to daptomycin therapy and matched them to patients who completed
therapy with vancomycin based on age, Acute Physiology and Chronic Health Evaluation
II score, and risk level of source.84 The decision to change therapy was based on a
vancomycin MIC of 1.5 or 2 mg/L as determined by E-test and use of daptomycin at the
time was restricted to infectious diseases service. Patients who were switched to
daptomycin were switched at a median time of 5 days and the majority was switched due
to lack of improvement or worsening on vancomycin. There were no statistically
significant differences between groups in a composite outcome of 60-day mortality,
microbiological failure, and recurrence (P=0.084), however 60-day mortality was
significantly lower (20% vs. 9%, P=0.046) in the group that was switched to
daptomycin.84 Because treatment changes were at the discretion of the treating physician,
there may have been selection bias where patients with higher MICs or who were
expected to do worse were switched to daptomycin. Additionally, there may have been
other factors contributing to poor outcomes. For instance, the study authors did not
comment on control of the source of infection between treatment groups. This study does
contribute to the question of vancomycin’s efficacy against MRSA with higher MICs and
whether this may be a potential role for daptomycin.

In another study, Murray and colleagues studied outcomes with early switch to
daptomycin based on vancomycin MIC.85 In accordance with an institutional policy,
patients who had MRSA with a vancomycin MIC >1 mg/L received daptomycin as soon
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as microbiological susceptibility data was available. Patients who received daptomycin
were matched by age, Pitt bacteremia score, and source of bacteremia to patients who
received vancomycin. Median duration of vancomycin therapy prior to daptomycin was
1.7 days. Crude analysis showed that daptomycin was superior to vancomycin in a
composite outcome of 30-day mortality and occurrence of persistent bacteremia (20% vs.
48.2%, P<0.001). This difference remained in multivariable logistic regression where
vancomycin patients had 4.5 times higher odds of clinical failure compared to
daptomycin. However, one limitation to this study is a change in practice standards as
microbiology testing methods changed from E-test to MicroScan during the study period.
These susceptibility testing methods are known to have different accuracy in estimating
vancomycin MIC.68 This study excluded central venous access-related infections, so most
clinical failures were in deep-seated infections such as IE and bone or joint infections.85
Widespread application of these studies is limited in that they represent the patient
population in one urban city with few comparative studies from other centers. The early
transition to daptomycin and minimization of vancomycin exposure resulting in better
outcomes is interesting, and the present study seeks to determine if that time to switch
plays a role in clinical outcomes.

Decreased susceptibility to daptomycin was seen in the study by Murray and colleagues
where 2.6% of patients receiving daptomycin experienced elevated MICs into the nonsusceptible range while on therapy.85 In the clinical trial by Fowler and colleagues, 5% of
patients developed reduced susceptibility to daptomycin while on treatment.78
Daptomycin non-susceptibility (DNS) in S. aureus has emerged in less than 10 years
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since the antibiotic’s approval with the first isolate identified in 2003.86 DNS is mediated
by two mechanisms: an increase in the positive charge of the cell membrane and
increased cell wall thickness.87,88 This increased positivity repels the calcium-daptomycin
complex and prevents the antibiotic from getting to its site of action. Increased cell wall
thickness prevents daptomycin from reaching the cell membrane. Both resistance
mechanisms effectively prevent membrane depolarization and leakage of cell contents
leading to cellular death. The clinical understanding of factors leading to emergence of
DNS is controversial. While some studies have suggested that it is related to vancomycin
exposure, this is an area of continued exploration since results of studies have been
mixed.87,89-91 The potential association between vancomycin exposure and DNS is
troubling since clinical guidelines and practice patterns advocate for the use of
vancomycin first line followed by daptomycin in patients who experience clinical decline
or failure on vancomycin therapy.75,92

Decreased daptomycin susceptibility has been observed in VISA isolates. Sader and
colleagues examined 207 previously collected S. aureus isolates and observed that 47%
of VISA isolates were also DNS with MICs > 1mg/L, in contrast to 100% of wild-type
MRSA and 100% of hVISA retaining daptomycin susceptibility.93 Though all hVISA
isolates in this study retained susceptibility to daptomycin, hVISA can preclude VISA
and thus by extension may preclude DNS.55 Patel and colleagues reviewed 917 S. aureus
isolates sent to the CDC.94 Of 70 isolates with vancomycin MIC between 4 and 16 mg/L,
almost 83% of them were DNS.94 An in vitro study by Sakoulas and colleagues
demonstrated both development of a vancomycin intermediate phenotype and increasing
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daptomycin MICs after 4 isolates of MRSA were exposed to vancomycin.89 It stands to
reason that daptomycin would have decreased activity against VISA because increased
cell wall thickness is one of the mechanisms behind DNS and contributes to VISA.88,95

The impact of previous vancomycin exposure on daptomycin susceptibility in S. aureus
isolates with retained vancomycin activity is less replicable. Moise and colleagues
conducted a study of 81 clinical MRSA isolates that showed a statistically significant
relationship between elevated vancomycin MICs and previous vancomycin exposure
(P=0.002) but this relationship was not demonstrated with daptomycin MICs
(P=0.111).87 While Bhalodi and colleagues were able to demonstrate reduced daptomycin
activity against an MRSA isolate in vitro after the isolate was exposed to vancomycin for
48 hours, they did not detect new DNS subpopulations.90 Using 5 clinical S. aureus
isolates that had reportedly become DNS, Rose and colleagues exposed isolates in vitro
to vancomycin for 4 days followed by daptomycin simulated at 6 mg/kg or 10 mg/kg for
4 days.91 Daptomycin retained activity against all strains with no difference in time to
achieve 99.9% killing between vancomycin pre-exposed and un-exposed simulations.
However, daptomycin was more potent against strains that were not pre-exposed to
vancomycin.

Until concrete evidence can be elucidated regarding the effect of vancomycin exposure
on daptomycin susceptibility in S. aureus, clinicians should be optimizing management
of S. aureus infections to preserve daptomycin’s clinical utility and prevent emergence of
DNS. Key clinical interventions include taking advantage of concentration-dependent
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activity to maximize daptomycin exposure by utilizing high doses, performing early
surgery on deep-seated infections with high inoculum to achieve source control, and
maintaining therapeutic vancomycin exposure.92
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CHAPTER TWO: RATIONALE, OBJECTIVES, and SIGNIFICANCE

Staphylococcus aureus is an aerobic, Gram positive bacterium naturally found as a
commensal organism on the skin of humans that can become an opportunistic pathogen
capable of causing a wide spectrum of disease.2 With its introduction into clinical
practice in 1940, penicillin revolutionized the treatment of infectious diseases, including
S. aureus; however resistance emerged as soon as 1942.6 In 1959, antibiotics that
remained stable against degrading enzymes produced by the organism were developed,
yet in 1961, methicillin-resistant isolates of S. aureus began to emerge.8 Though many
antibiotics have been developed to combat S. aureus, the organism has developed
resistance to most of them and thus they are not utilized first line like vancomycin.

Community-acquired (CA-MRSA) and hospital-acquired (HA-MRSA) cause distinct
infectious syndromes in different patient populations. Annual incidence of SAB is
estimated between 4.7 and 38.2 per 100,000 patient-years.13,15 S. aureus was responsible
for over 12,000 nosocomial infections from 2009-2010.9 Mortality from SAB is
considerable with an overall 30-day mortality rate estimated at 20% and mortality after
one-year as high as 62%.17,18 Risk factors for S. aureus infection include
immunocompromised state, diabetes, substance abuse, age, presence of central venous
catheters, and IV drug use.2,14,19,20,23

Vancomycin has been widely used since the 1980s demonstrated an increasing incidence
of MRSA, and little resistance has developed in the last 30 years. However, S. aureus has
developed decreased susceptibility to the drug through alterations in cell wall thickness
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and overproduction of antimicrobial targets.48,50 Individual S. aureus microbes with
decreased susceptibility can exist as subpopulations of an otherwise susceptible isolates, a
phenomenon known as hVISA. Heteroresistance is speculated to play a role in therapy
failure of vancomycin against S. aureus and an epidemiologic shift to more S. aureus
isolates have MICs at the upper end of the susceptibility range; however the accuracy of
different susceptibility testing procedures must be considered in determining the impact
of this vancomycin MIC creep.68-70 One rationale for treatment failure at higher MICs
includes limited ability to reach pharmacodynamic targets for optimal bactericidal
activity using safe medication doses.76 The need to balance the use of efficacious dosing
while minimizing adverse events has led individual clinicians to choose alternative
therapeutic agents for treatment of MRSA BSI.

Daptomycin carries indications for SSTI and BSI due to S. aureus, is not associated with
nephrotoxicity, and requires less monitoring. While practice guidelines endorse
daptomycin as an alternative to vancomycin, no clinical trials have demonstrated
superiority of daptomycin to vancomycin. Current clinical guidelines support a change in
therapy guided by patient clinical status.75 Some single-center studies have suggested
better outcomes with daptomycin against SAB with higher vancomycin MICs or when
switched early in treatment course.84,85 Daptomycin non-susceptibility has been
encountered clinically and some studies suggest it may be related to previous vancomycin
exposure. VISA strains have demonstrated DNS, but this has been less replicable with
hVISA strains and vancomycin susceptible strains.87,89-91,93,94

20

The primary objective of this study is to compare clinical outcomes in patients receiving
treatment for S. aureus bacteremia who switch from vancomycin to daptomycin early
(after 1-3 days), intermediately (after 4-7 days), or late (after 8 days or more) in
treatment. The central hypothesis of this study is that there are differences in clinical
outcomes among patients who switched from vancomycin to daptomycin early,
intermediately, and late in therapy for S. aureus bacteremia. Clinical failure was defined
as recurrent positive blood cultures for S. aureus within 30 days of first positive blood
culture, death within 60 days after first blood culture positive for S. aureus, and all-cause
readmission within 90 days after first blood culture positive for S. aureus.

Secondary outcomes were to describe the patient population that is switched early,
intermediately, and late and to determine what patient factors are associated with
treatment failure. Data collected to describe these patients include demographic
characteristics, comorbidity measures, severity of illness measures, infection
characteristics, concomitant antibiotics received, and safety outcomes measures.
Multivariable logistic regression models were constructed to determine independent
patient factors associated with treatment failure.

This study is significant because it contributes to previously published literature
regarding daptomycin versus vancomycin use in S. aureus bacteremia. It further explores
previously hypothesized relationships between vancomycin MIC and daptomycin use,
and time to switching to daptomycin and patient outcomes. Previous meta-analyses have
raised questions regarding vancomycin efficacy in SAB when the vancomycin MIC is
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greater than 1 mg/L, and have hypothesized that this could be a niche for daptomycin.17
One retrospective observational study showed that when vancomycin is switched to
daptomycin early based on higher vancomycin MIC, the patients switched to daptomycin
had lower clinical failure rates.85 Patients from this study would fall into the early therapy
switch of the present study, and early switch patients will be compared directly to
patients who are on vancomycin for a longer period before switching. Additionally, the
distribution of vancomycin MICs for S. aureus isolates will be observed among groups
and if there any differences in outcomes. Another retrospective study showed a mortality
benefit when switching from vancomycin to daptomycin intermediately in treatment.84
The present study will help bridge knowledge gaps from these previous studies by being
the first to directly compare patients initiated on vancomycin and switched to daptomycin
at different time frames. This study helps determine if the extent of previous vancomycin
exposure before switching to daptomycin plays a role in clinical outcomes.
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CHAPTER THREE: METHODS

Study Design
A retrospective cohort design was utilized for this study. Patients were included if they
were at least 18 years of age at the time of admission, admitted between January 1, 2010,
and December 31, 2014, received vancomycin and daptomycin during hospitalization,
had an International Classification of Diseases, 9th revision (ICD-9) code of interest billed
for during admission, and had S. aureus identified from blood culture. Only the first
admission per patient during that time period was included for analysis.

Since the study investigator examined patients who were initiated on vancomycin and
then therapy was changed to daptomycin, patients had to receive both medications.
Medication administration data was utilized to determine duration of therapy. In order to
adequately ascertain clinical outcomes, patients were excluded if the total duration of
vancomycin and daptomycin was less than 3 days.

ICD-9 codes used to determine enrollment were V09.0 “infection with microorganisms
resistant to penicillin”, 038.11 “S. aureus septicemia”, 038.12 “Methicillin resistant S.
aureus septicemia”, 041.11 “S. aureus infection, site unspecified”, or 041.12 “Methicillin
resistant S. aureus infection, site unspecified”.96
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Data Source
Subjects were identified and data was collected using the University of Kentucky (UK)
Enterprise Data Trust (EDT) through the Center for Clinical and Translational Science
(CCTS), which is supported by the National Center for Advancing Translational
Sciences, National Institutes of Health, through grant number UL1TR000117. The CCTS
EDT is maintained by a biomedical informatics team and the Institute for Pharmaceutical
Outcomes and Policy at UK to house clinical data from different electronic systems at
UK HealthCare (UKHC). As of December 2015, the clinical data set currently
encompasses 554,300 lives admitted as inpatients to UKHC from 2006 on.97 The EDT
has search dimensions for information on demographics, financial classification, provider
level detail, medical diagnosis (ICD-9 standard), medical procedures (current procedural
terminology [CPT] codes), laboratory tests and results, medications administered, visit
details, and vital signs. The UK Institutional Review Board (IRB) has granted umbrella
approval for the use of de-identified EDT data for research purposes, and the current
study was approved by the UK IRB for use of identified EDT data. Clinical data was
collected on identified subjects and is listed in Appendix A. CPT codes for source control
procedures are listed in Appendix B. Specific data source variables used in the project are
detailed in Appendix C.
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Definitions
Patients were stratified based on time to change in therapy from vancomycin to
daptomycin. They were a priori assigned to the early switch group if therapy was
changed after 1-3 days on vancomycin therapy, the intermediate switch group if therapy
was changed in 4-7 days, or late switch group if therapy was changed at 8 days or longer.

Time to positive cultures reflects the length of time from admission to diagnosis of
bloodstream infection by positive cultures.

A patient was determined to have other infectious organisms if an organism other than S.
aureus grew from subsequent blood cultures or other tissue samples. Contaminants and
colonization were excluded from the definition of other infectious organisms. An isolate
was determined to be a contaminant if it grew in blood from only one bottle in a set and
did not undergo further microbiological work-up. Isolates determined to represent
colonization include Candida species or Enterococcus species isolated from respiratory
sources, less than 100,000 colony-forming units (CFU) of organism from urine, and less
than 10,000 CFU of organism isolated from respiratory source. The presence of enteric
Gram negative organisms, Enterococcus species, or Candida species from stool culture
also was considered colonization as these organisms represent normal flora.
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Treatment failure is defined as all-cause mortality at 60 days from first positive blood
culture, recurrence of S. aureus in bloodstream within 30 days from initial clearance of
blood cultures, or all-cause readmission within 90 days.

Outcomes
The primary outcome is treatment success or treatment failure. Secondary outcomes
included the assessment of each individual component defining treatment success or
failure and safety outcomes (development of renal injury per RIFLE criteria, diagnosis
with Clostridium difficile infection, and rhabdomyolysis or creatine kinase elevation
>1500 units/mL). Rhabdomyolysis was identified using the ICD-9 code 728.88
“rhabdomyolysis”.98 Use of the ICD-9 code 00.845 “intestinal infection due to C.
difficile” has been shown to be highly sensitive and specific for identifying C. difficile
infection.99

RIFLE is an acronym for risk of renal dysfunction, injury to the kidney, failure of kidney
function, loss of kidney function, and end-stage kidney disease. It is a classification
system for assessing acute renal failure. It considers change from baseline, acute on
chronic renal disease, sensitivity and specificity, and can be applied across multiple
centers.100 Table 3.1 describes the RIFLE classification for acute renal failure.
Glomerular filtration rate was calculated using a modified Cockcroft-Gault equation that
omitted body weight from the equation.101 Temporality for defining loss of kidney
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function and end-stage kidney disease could not be assessed, therefore only risk, injury,
and failure were assessed as acute kidney injury.

Table 3.1: Classification scheme for acute renal failure per RIFLE criteria100
Class

Glomerular Filtration Rate (GFR)
Criteria

Urine Output Criteria

Risk

Increased SCr x1.5 or GFR decrease
>25%

<0.5 mL/kg/hr x6 hours

Injury

Increased SCr x2 or GFR decrease
>50%

<0.5 mL/kg/hr x12 hours

Failure

Increase SCr 3x or GFR decrease
75% or SCr >4 mg/dL

<0.3 mL/kg/hr x24 hours or
anuria x12 hours

Loss

Persistent acute renal failure >4 weeks

End-stage
kidney disease

Complete loss of kidney function >3 months

Statistical Analysis
All statistical comparisons were performed using SAS® version 9.3 (Cary, NC) statistical
software. A Shapiro-Wilks test was performed to determine normality and all variables
were found to be statistically significantly different from normal, thus nonparametric
statistical tests were employed for analysis. Baseline descriptive statistics are reported as
median and interquartile range for continuous data or proportions for categorical data.
Fisher’s exact test will be used to compare distribution of categorical data. Wilcoxon rank
sum test will be used to compare distribution of continuous data. The analysis of variance
(ANOVA) test was used to compare multiple groups. An alpha level of <0.05 was set to
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determine statistical significance. To determine independent predictors of success, a
multivariable logistic regression model will be constructed to determine odds ratios with
clinical success as the outcome of interest. Backward elimination with an alpha
significance level of 0.05 was carried out to determine the final model. The Akaike
Information Criterion (AIC) and AUC were used to determine the most predictive model.
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CHAPTER FOUR: RESULTS

There were 2,784 admissions for adult patients hospitalized between January 1, 2010, and
December 31, 2014 billed for at least one of the including ICD-9 codes. Of those ICD-9
codes, 0.7% of encounters were encoded for V09.0 “infection with microorganisms
resistant to penicillin, 7.5% were coded for 038.11 “S. aureus septicemia”, 10% were
coded for 038.12 “methicillin-resistant S. aureus septicemia”, 34.4% were coded for
041.11 “S. aureus infection, site unspecified”, and 51% were encoded for 041.12
“methicillin-resistant S. aureus, site unspecified”. Three hundred sixty seven patients
received at least one dose of both vancomycin and daptomycin. Of that 367, 195 had
blood cultures positive for Staphylococcus aureus. When patients who received less than
3 days of total therapy were excluded, the final data set included 193 patients. Forty-nine
patients (25.4%) were in the early switch group, 76 patients (39.4%) were in the
intermediate switch group, and 68 patients (35.2%) were in the late switch group.
Baseline characteristics for the final cohort and each treatment group are presented in
table 4.1.
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Table 4.1: Baseline characteristics of final cohort, reported as n(%) or median
(interquartile range)

Gender
Male
Female
Race
White
African American
Other
Age, years
Charlson
comorbidity index
Admitted to intensive
care unit
History of
intravenous drug use
Cardiac prosthesis
Time to positive
culture, days
MRSA
Vancomycin MIC,
mg/L
1
2
Daptomycin MIC,
mg/L
<1
>1
E-test performed
Length of stay, days
Source control
achieved
Cardiac
Skin/soft tissue
Bone/joint
Central venous
access
Duration of therapy,
days

Total
Cohort
N=193

Early
N=49

Intermediate
N=76

119 (62%)
74 (38%)

30 (61%)
19 (39%)

49 (64%)
21 (36%)

171 (89%)
17 (9%)
5 (2%)
48 (35-59)

43 (88%)
5 (10%)
1 (2%)
50 (36-59)

71 (93%)
3 (4%)
2 (3%)
45.5 (35-59.5)

4 (3-7)

5 (3-8)

4 (3-7)

40 (59%) 0.77
28 (41%)
0.31
57 (84%)
9 (13%)
2 (3%)
48 (350.68
58)
4 (3-6)
0.52

26 (13%)

5 (10%)

10 (13%)

11 (16%) 0.67

34 (18%)

8 (16%)

16 (21%)

10 (15%) 0.60

9 (5%)
2.9 (2.0-5.1)

6 (8%)
2.2 (1.8-3.3)

142 (74%)

2 (4%)
2.1 (1.83.5)
29 (59%)

1 (1%)
0.23
4.0 (2.0
0.0005
– 10.0)
49 (72%) 0.008
0.0016

160 (83%)
31 (16%)

35 (73%)
12 (25%)

57 (80%)
14 (20%)

64 (84%)

Late
N=68

Pvalue

65 (96%)
3 (4%)
0.45

189 (98%)
4 (2%)
46 (24%)
24 (13-47)

49 (100%)
0
13 (27%)
20 (10-26)

73 (96%)
3 (4%)
23 (30%)
20 (11-39.5)

71 (37%)
17
3
53
5

18 (37%)
1
0
14
3

36 (47%)
13
2
24
1

16 (9-27)

7 (4-16)

13 (8-23.5)

30

67 (99%)
1 (1%)
10 (15%) 0.076
42 (21.5- <0.00
55.5)
01
0.021
17 (25%)
3
1
15
1
23.5
<0.00
(15.5-42) 01

Polymicrobial
bloodstream
infection
Other infectious
organisms
Gram negative
Gram positive

17 (9%)

3 (6%)

5 (7%)

9 (13%)

80 (41%)

13 (27%)

27 (35%)

52 (27%)
36 (19%)

8 (16%)
1 (2%)

18 (24%)
13 (17%)

Fungal from nonurinary source
Concomitant MRSA
therapy
Ceftaroline
Gentamicin
Rifampin
Trimethoprim/
Sulfamethoxazole
Other antibiotics
Cefepime
Cefazolin
Meropenem
Nafcillin
Piperacillin/
Tazobactam
Tobramycin or
Amikacin
Amphotericin
formulation
Daptomycin dose,
mg/kg
Initial vancomycin
trough, mg/L

14 (7%)

3 (6%)

2 (3%)

40 (59%) <0.00
01
28 (38%) 0.0245
22 (32%) <0.00
01
9 (13%) 0.063

38 (20%)
31 (16%)
23 (12%)
10 (5%)

12 (24%)
8 (16%)
6 (12%)
0

19 (25%)
13 (17%)
10 (13%)
8 (11%)

7 (10%)
10 (15%)
7 (10%)
2 (3%)

0.045
0.94
0.85
0.023

63 (33%)
31 (16%)
24 (12%)
32 (17%)
119 (62%)

17 (35%)
9 (18%)
4 (8%)
11 (22%)
23 (47%)

23 (30%)
13 (17%)
10 (13%)
11 (14%)
45 (59%)

23 (34%)
9 (13%)
10 (15%)
10 (15%)
51 (75%)

0.85
0.75
0.60
0.47
0.0069

29 (15%)
11 (6%)

4 (8%)
0

7 (9%)
4 (5%)

18 (26%) 0.0069
7 (10%) 0.046

8.0 (6.0-9.6)

8.6 (6.29.7)
21.5 (11.229.8)

8.6 (6.0-9.6)

7.7 (6.09.4)
13.2
(9.523.3)
89.72
(47.16128.26)
62 (27.5176)

13.3 (9.323.3

Baseline GFR*,
mL/min

13 (8.5-20.6)

80.67
68.50
80.67 (51.24(45.67(41.38131.61)
125.43)
111.86)
Baseline CK, units/L
60.5 (2783 (31.544 (24-134.5)
174)
189.5)
MRSA=methicillin-resistant Staphylococcus aureus
CK=creatine kinase
*creatinine clearance calculated by modified Cockcroft-Gault equation

0.32

0.56
0.076

0.14

0.70

Sixty-two percent of the cohort was male. The racial distribution was representative of
the largely Caucasian state with whites making up 89%. The cohort was middle aged
31

with a median age of 48 years (IQR, 35-59 years). Thirteen percent of patients were
admitted to the intensive care unit. A history of intravenous drug abuse was reported in
18% of patients. Median length of stay was 24 days, but the late treatment switch group
had a significantly longer length of stay of 42 days (P<0.0001). Median time to positive
blood cultures from admission was 2.9 days with the late group having a significant
longer time to positive cultures of 4.0 days (P=0.0005).

Seventy-four percent of patients in the cohort had MRSA bacteremia, with the early
switch therapy group having a significantly lower proportion of MRSA cases at only 54%
(P=0.008). While most of these cases (83%) had a vancomycin MIC of 1 mg/L, the late
group had significantly higher proportion of isolates with a vancomycin MIC of 1 mg/L
(96%, P=0.0016). MICs were tested by E-test for 24% of all S. aureus isolates.
Daptomycin susceptibility was 98% for the entire cohort. Median time to collection of
clear blood cultures was one day. The source of infection was controlled in 37% of the
cohort with 47% of patients in the intermediate group achieving source control and only
25% in the late group achieving source control (P=0.021).

Median duration of therapy was 16 days, but duration of therapy was significantly shorter
in the early group and longer in the late group (7 days vs. 23.5 days, P<0.0001). Fortyone percent of patients had other infectious organisms identified during hospitalization,
and there were significant differences between groups with 59% of patients in the late
group growing at least one concomitant organism. Patients in the late group had
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significantly more Gram negative, Gram positive, and fungal concomitant organisms
compared to patients in the early and intermediate groups. Daptomycin dosing was not
significantly different between groups with a median weight-based dose of 8.3 mg/kg for
the entire cohort. Median first vancomycin level also did not differ between groups with a
median level of 13.1 mg/L. Twenty percent of patients also received ceftaroline during
hospitalization, but this was significantly lower in the late group with only 10% of
patients receiving concomitant ceftaroline (P=0.045). Five percent of patients received
concomitant sulfamethoxazole/trimethoprim, but a significant proportion (11%) of those
patients were in the intermediate group (P=0.023). While the majority of patients (62%)
in the cohort received piperacillin/tazobactam during hospitalization, there were
significantly fewer in the early switch group and significantly more in the late switch
group (47% vs. 75%, P=0.0069). Patients in the late switch group also received
significantly more amikacin or tobramycin (26% vs. 15%, P=0.0069) and amphotericin
(10%vs. 6%, P=0.046) during hospitalization than the overall cohort.

Median baseline creatinine clearance was not different between groups with a value of
98.4 mL/min for the cohort. Median baseline CK value was 60.5 units/L and this did not
differ between groups.

Treatment outcomes are reported in table 4.2. Treatment failure occurred in 18% of
patients with no differences between groups. None of the components of the definition of
treatment failure differed between groups.
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Table 4.2: Treatment outcomes, reported as n (%)

30-day recurrence of S.
aureus from blood culture
60-day mortality
90-day readmission
Treatment failure

Total
Cohort
N=193
2 (1%)

Early
N=49

Intermediate
N=76

Late
N=68

Pvalue

1 (2%)

1 (1%)

0

15 (8%)
19 (10%)
34 (18%)

3 (6%)
6 (12%)
9 (18%)

6 (8%)
6 (8%)
13 (17%)

6 (9%)
0.94
7 (10%) 0.71
12 (18%) 1.0

0.72

Multivariate logistic regression analysis was performed. Variables put into the initial
model were for treatment group, history of IV drug use, vancomycin MIC, ceftaroline
therapy, sulfamethoxazole/trimethoprim therapy, piperacillin/tazobactam therapy,
tobramycin or amikacin use, amphotericin therapy, and other infectious organisms
(Appendix D). When performing backwards elimination and using AIC and AUC to
determine the final model, time to positive cultures, length of stay, and other infectious
organisms provided the model with the best fit (table 4.3). When controlling for other
covariates, logistic regression showed that time to positive cultures and length of stay
were significant independent predictors of treatment success. For every one day from
admission until positive cultures, there was a 4% decreased odds of treatment success
(OR 0.961, 95% CI 0.927 – 0.997). For every one additional day spent in the hospital,
odds of treatment success increased by roughly 4% (OR 1.036, 95% CI 1.009 – 1.063).
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Table 4.3: Odds ratios determined by logistic regression results using treatment
success as the outcome of interest.
Adjusted Odds Ratio
Estimate

95% Confidence
Interval

Time to positive
cultures

0.961

0.927

0.997

0.057

Length of stay

1.036

1.009

1.063

0.0079

Other infectious
organisms

0.517

0.225

1.184

0.12

P-value

Safety outcomes are reported in table 4.4. The incidence of C. difficile was low in the
cohort with only 2% of patients being diagnosed during admission. Rhabdomyolysis
occurred in 6% of patients. Nephrotoxicity per RIFLE criteria occurred in 43% of
patients. There were no differences between groups in occurrence of adverse outcomes.
Nephrotoxicity was experience by 41% of patients in the early switch group, 35% of
patients in the intermediate group, and 53% of patients in the late switch group (P=0.1).

Table 4.4: Safety outcomes, reported as n (%)

Rhabdomyolysis
Clostridium difficile
Nephrotoxicity

Total
Cohort
N=193
12 (6%)
3 (2%)
83 (43%)

Early
N=49
3 (6%)
0
20 (41%)
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Intermediate
N=76
4 (5%)
1 (1%)
27 (35%)

Late
N=68
5 (7%)
2 (3%)
36 (53%)

Pvalue
0.93
0.62
0.1

CHAPTER FIVE: DISCUSSION

This study of 193 patients with S. aureus bacteremia who initiated treatment on
vancomycin and were switched to daptomycin found no difference in patient outcomes
based on time to therapy switch. There was no difference in treatment failure between
patients switched from vancomycin to daptomycin early after treatment initiation, at an
intermediate time frame, or late after initiation for SAB. Unlike previous studies, all
patients in the present study were switched from vancomycin to daptomycin rather than
having a comparator group that remained on vancomycin. This study accepts the finding
from Fowler and Moore that daptomycin is non-inferior to vancomycin, but builds upon
the work of Moore and Murray by attempting to further elucidate when daptomycin
should be utilized over vancomycin.78,84,85 The treatment failure rate remains roughly 1520%, which is consistent with estimates of overall mortality rates of 20%, with mortality
one component of most study definitions of clinical failure.17,102

Factors that were associated with treatment success were time to positive cultures and
length of stay. An extended time to positive cultures was associated with decreased
likelihood of clinical success. S. aureus is one of the most common organisms isolated in
nosocomial-acquired infections.9 With a median time to positive culture of 4 days in the
late switch group, most of the BSIs would meet the definition of nosocomial infection,
where the definition is positive blood culture obtained from patients hospitalized for 48
hours or longer.103 A study by Klevens et al did not demonstrate a higher mortality rate
with healthcare-onset SAB vs. community onset SAB, but a study by Cosgrove et al
showed that nosocomial SAB is associated with significantly longer length of stay.16,102
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Longer length of stay was associated with increased likelihood of treatment success as for
each day a patient was admitted to the hospital, the odds of treatment success increased
by 3%. This is likely a reflection of practice patterns at this institution where patients
remain in the hospital for a prolonged period of time to complete therapy. A survey of
hospital medicine and infectious diseases physicians conducted at the University of
Kentucky revealed that barriers to discharging persons who inject drugs to complete IV
antibiotic therapy include socioeconomic factors and the potential risk of the patient
misusing the peripherally-inserted central catheter.104 While participants coded for a
history of IV drug use represented a smaller proportion and was not associated with
treatment success in the current study population, IV drug use is a known risk factor for
developing S. aureus infection.22

Patients in the late switch therapy group had significantly longer lengths of stay than
patients in the early or intermediate switch group. Significantly lower rates of source
control and longer durations of antibiotic therapy in the late switch group indicate that
these patients likely had complicated bacteremia. Source control is the ultimate cure for
SAB.105-107 The longer length of stay is reflective of the longer duration of antibiotic
therapy given practice patterns of the institution as previously discussed. While there
were no differences in Charlson comorbidity index or ICU admission to indicate higher
severity of illness in the late switch group, these patients more commonly received
piperacillin/tazobactam, aminoglycosides, and amphotericin during their admission. They
also had more concomitant Gram negative and Gram positive infections indicating they
could have had more severe manifestations of infection requiring such broad spectrum
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coverage. These agents also cause nephrotoxicity when administered concomitantly with
vancomycin, potentially leading to later switch in therapy as nephrotoxic adverse effects
began to manifest.60,108-110 This is supported by a trend toward a higher rate of
nephrotoxicity in the late switch group. Nephrotoxicity has been shown to lead to
increased lengths of stay.111,112 Charlson comorbidity index, which is a marker of
expected one-year morality, may not be the best indicator of severity of illness in this
patient population.113 However, this index was readily available in the administrative data
set, unlike some other markers of illness severity such as Pitt bacteremia score which
assesses patients on the day of positive blood cultures and incorporates subjective data
such as mental status.114

Additional trends where shown between groups with regard to initial vancomycin trough
and E-test as the susceptibility method performed. Patients in the early switch group had
a higher median initial vancomycin trough level. The median level seen in that group is
above the currently recommended therapeutic trough range of 10-20 mg/L.41,115 High
vancomycin trough levels are associated with higher probability of developing
nephrotoxicity.60,76,109,116 Patients in this group may have been proactively switched to
daptomycin earlier in early recognition of the potential for nephrotoxicity, especially
since they had the lowest baseline GFR. Patients in the late switch group had the lowest
proportion of S. aureus isolates tested in the clinical microbiology laboratory by E-testing
method. For the majority of this study period, susceptibility testing from all blood culture
isolates was performed using an automated susceptibility testing method called BD
PhoenixTM. In summer of 2013 through the end of the study period, the clinical
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microbiological lab began performing E-testing on all MRSA isolates from blood culture.
Microbiological testing methods are not created equally. BD PhoenixTM tends to
underestimate the MIC for vancomycin against S. aureus while E-testing tends to be a
conservative testing method that often overestimates the MIC.68,70 Previously published
meta-analyses demonstrated adverse clinical outcomes when the vancomycin MIC was
greater than 1 mg/L by E-test, which may have led to earlier changes in therapy in the
early and intermediate switch groups.71-73 Clinicians treating patients in the late switch
group could have been following current IDSA guidelines to let clinical status rather than
MIC guide therapy change decisions, and thus switched therapy to daptomycin in a later
time frame.75

Another trend existed between groups and concomitant fungal organisms isolated from
non-urinary sources. Patients in the late therapy switch group had more non-urinary
fungal organisms isolated during hospitalization than patients in the early and
intermediate switch groups. Thirteen isolates were Candida species. One isolate was a
Cryptococcus neoformans bloodstream infection. Of the Candida isolates, C. albicans
comprised 23% of fungal isolates. The other 77% were non-albicans species with C.
glabrata making up 46% of the non-albicans isolates. Invasive candidiasis comprises
Candida bloodstream infections and other deep-seated tissue infections due to Candida
and is associated with a 40% mortality rate.117 One of the risk factors for invasive
candidiasis is broad-spectrum antibiotic use.117 Candida infections represent the 7th most
common cause of healthcare-associated infections.9,118 Patients in the late therapy switch
group had significantly higher use of broad-spectrum antibiotic therapy and significantly
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longer lengths of stay compared to patients in other groups, and thus were pre-disposed to
more fungal infections. While C. albicans has historically been the dominant Candida
species, non-albicans species have increased in prevalence. Surveillance data from 40
hospitals located in the Atlanta and Baltimore metropolitan over a 5-year period
demonstrated a 64% non-albicans rate with C. glabrata making up the largest proportion
of those isolates; these numbers are comparable to the prevalence of Candida species in
this cohort.119

There are several limitations to consider with this study. First, this was a retrospective
study using data that was already collected for the purposes of diagnosis and treatment of
disease, not for research purposes. Patients were identified through use of ICD-9 codes
submitted for administrative purposes and reimbursement. ICD-9 codes used to
determine enrollment were V09.0 “infection with microorganisms resistant to penicillin”,
038.11 “S. aureus septicemia”, 038.12 “Methicillin resistant S. aureus septicemia”,
041.11 “S. aureus infection, site unspecified”, or 041.12 “Methicillin resistant S. aureus
infection, site unspecified”.96 Previously conducted studies using these ICD-9 codes to
identify incident S. aureus infections from administrative data have demonstrated low
sensitivity of 24-65% but high specificity of 99%.120,121 The low sensitivity for
identifying incident infections may be due to errors in coding including history of S.
aureus infection or colonization. To increase the specificity in this study, the query of
encounters with those diagnoses codes were cross-referenced with microbiological data
specific for S. aureus isolated from blood cultures.
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The use of microbiological data could have excluded a substantial proportion of patients
referred to this institution from outside institutions. While transferred patients were not
excluded explicitly, treatments received at an outside facility may have influenced
treatment decisions and patient outcomes at this institution. Transferred patients could
only be included if they had blood cultures growing S. aureus collected at this institution,
leaving opportunity for misclassification of duration of bacteremia and recurrence of
infection.

This methodology resulted in a smaller sample size which may limit the external validity
of these results to other centers. Data herein represents one tertiary care medical center
that serves as a referral center for a large geographical area comprising central and
eastern Kentucky. This study would not meet power to detect a meaningful clinical
difference in treatment failure between early, intermediate, and late therapy switch as
evidenced by the equal rates of treatment failure across groups. Compared to other
studies comparing vancomycin and daptomycin, the sample size in this study is
comparable in size with less than 200 subjects in total.84,85

With respect to assessment of the key response variables, there are a few caveats to
consider. The primary outcome consisted of all-cause mortality and all-cause
readmission. Due to the limitations of using administrative coding and administrative
data to assemble a data set, determining infection-related outcomes would be impractical
without conducting retrospective chart review. Because the administrative data set
consisted of one clinical data warehouse from one institution, only readmissions to the
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studied institution could be ascertained. Additionally, information on outpatient
completion of antibiotic therapy could not be ascertained without coordinating data with
third party claims databases. Missing values are a routine challenge when working with
administrative data and values must be imputed in some cases, which are detailed in
Appendix C.

This is the first study to directly compare differences in outcomes based on time to
changing therapy and adds to a body of literature comparing vancomycin to daptomycin
in clinical practice. Moore and colleagues conducted a study of patients switched from
vancomycin to daptomycin after a median of 5 days with the rationale for therapy switch
from vancomycin being lack of improvement or worsening on treatment.84 The primary
outcome was clinical failure, a composite of 60-day mortality, persistent bacteremia at 7
days from index culture, and 30-day recurrence. The rate of clinical failure was 17%.
Murray and colleagues specifically studied patients who were switched to daptomycin
early in the course of therapy based on vancomycin MIC at a median time of 1.7 days.85
Their composite clinical failure outcome was defined as 30-day mortality and persistent
bacteremia. Twenty percent of patients switched to daptomycin experienced clinical
failure.

Treatment failure rates from the current study were directly compared to treatment failure
rates from the studies by Moore and Murray (table 5.1). Examining the composite of 60day mortality and 30-day recurrence of MRSA BSI the treatment failure rate in the cohort
from Moore and colleagues was 12%. Examining the composite of 30-day mortality, 30-
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day recurrence of MRSA BSI, and 30-day readmission, the treatment failure rate in the
cohort from Murray and colleagues was 22%. Analyzing these rates compared to
treatment failure rates of 18%, 17%, and 18% respectively in the early switch,
intermediate switch, and late switch groups in the current study, there was no statistically
significant differences in treatment failure between groups (p=0.62). There were no
statistically significant differences in mortality or recurrence between the studies.
Excluding data from the Moore study since readmission was not an outcome of interest,
there were no differences in readmission between the current study and the Murray
cohort. There was no difference in treatment failure between the Moore cohort – with a
median time to switch of 5 days – and the intermediate switch group in the current study
(12% vs. 17%, p=0.47). There was no difference in treatment failure between the Murray
cohort – switched at 1.7 days – and the early switch group in the current study (22% vs.
18%, p=0.66).

Table 5.1: Comparing treatment outcomes between Tennant, Moore, and
Murray, reported as n (%)84,85

30-day recurrence
of S. aureus from
blood culture

Total
Cohort
N=337

Early
N=49

Intermediate
N=76

Late
N=68

4 (1%)

1
(2%)

1 (1%)

0

Moore Murray
N=59
N=85

Pvalue

2 (3%)

0.23

0

3
6
6 (8%)
5 (1%) 3 (1%)
0.64
(6%)
(9%)
90-day
35
6
7
16
6 (8%)
-0.20
readmission
(13%) (12%)
(10%)
(19%)
60
9
12
7
19
Treatment
13 (17%)
0.62
(18%) (18%)
(18%) (12%)
(22%)
failure
-- Readmission was not an outcome of interest in the study by Moore and colleagues.84
60-day mortality

23 (7%)
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Future study should move away from comparing daptomycin and vancomycin directly
and should instead focus on identifying which patient factors are risk factors for clinical
failure, which are associated with clinical success, and how to recognize these as quickly
as possible to optimize patient outcomes. The key to vancomycin compared to
daptomycin lies in optimizing use of each agent. Vancomycin exposure and
subtherapeutic vancomycin levels have been associated with DNS and hVISA
isolates.90,92 Identifying patients who have previously been exposed to vancomycin or
who are likely to have suboptimal vancomycin levels may be targets for early initiation of
daptomycin. Further clarifying the ideal time to therapy switch and the ideal duration of
each vancomycin and daptomycin are other questions to answer.

Paramount to patient success is optimizing management of SAB independent of
antimicrobial therapy. Ensuring clearance of bacteremia is vital as persistent
staphylococcal bacteremia is associated with 10-times higher risk of relapse and 2.6times higher odds of in-hospital mortality.75,122 Patients with relapsed SAB are likely to
be re-exposed to vancomycin, and multiple exposures should be minimized to reduce the
risk of decreased susceptibility vancomycin and daptomycin. A study by Carugati and the
International Collaboration on Endocarditis demonstrated that in patients with MRSA IE,
patients definitively treated with daptomycin cleared bacteremia faster than patients
treated with standard-of-care regimens, including vancomycin (1.0 day vs. 5.0 days,
[p<0.01]).123 This supports switching to daptomycin in persistent bacteremia, though
ensuring optimal vancomycin levels is also important to ensuring expedient clearance of
blood cultures.41,124,125 In a case-control study comparing patients with persistent SAB to
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patients with resolving bacteremia, initial vancomycin trough less than 15 mg/L was
associated with 4-times higher odds of having persistent SAB (OR, 4.25 [95% CI, 1.5111.96]).125 Utilizing vancomycin and daptomycin in combination regimens with a betalactam for persistent bacteremia is a present topic of several studies.29,88 As previously
discussed, source control to remove nidi of infection is the ultimate cure for SAB.106,107
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CHAPTER SIX: CONCLUSION

This is the first study to directly compared patients switched from vancomycin to
daptomycin for treatment of S. aureus bacteremia. Patients were stratified into groups
based on early therapy switch (within 1-3 days of starting treatment), intermediate
therapy switch (within 4-7 days of starting treatment), or late therapy switch (after 7 days
of treatment). This study did not detect a difference in treatment failure rates, defined as
30-day recurrence of S. aureus from blood culture, 60-day all-cause mortality after first
positive blood culture, or 90-day all-cause readmission after first positive blood culture.
Length of stay was positively associated with treatment success while time to positive
cultures was negatively associated with treatment success.

Future research directions should focus on optimizing use of vancomycin and
daptomycin and medical management of SAB. Previous vancomycin exposure and
suboptimal vancomycin concentrations are associated with decreased vancomycin and
daptomycin susceptibility. Future studies can identify patients at risk for multiple
vancomycin exposures. Which patient factors are risk factors for clinical failure, which
are associated with clinical success, and how to recognize these as quickly as possible to
optimize patient outcomes are questions that still need to be answered.
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APPENDIX A
Clinical Data Points Queried from University of Kentucky HealthCare Enterprise Data
Trust
ICD 9 Code
Clinical Data Point
(if applicable)
Demographics
Age at admission
Gender
Race
Admission height
Admission weight
Body mass index
Inpatient location history
Clinical History
Charlson comorbidity index
History of intravenous drug abuse
Drug dependence

304.xx

Other, mixed, or unspecific drug abuse, unspecified

305.90

Presence of cardiac prosthesis
Heart valve replaced by other means

V43.3

Automatic implantable cardiac defibrillator in situ

V45.02

Cardiac pacemaker in situ

V45.01

Osteoarticular source of infection
Osteomyelitis periostitis and other infections involving bone
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730.xx

Infection and inflammatory reaction due to internal joint
prosthesis

996.66

Infection and inflammatory reaction due to other internal
orthopedic device, implant, or graft

996.67

Abscess of spinal cord

324.1

Other sources of infection
Bloodstream infection due to central venous catheter
Infection and inflammatory reaction due to cardiac device,
implant, or graft
Infection and inflammatory reaction due to nervous system
device, implant, or graft
Infection and inflammatory reaction due to indwelling urinary
catheter device, implant, or graft
Infection and inflammatory reaction due to other genitourinary
device, implant, or graft
Infection and inflammatory reaction due to peritoneal dialysis
device, implant, or graft
Infection and inflammatory reaction due to other internal
prosthetic device, implant, or graft

Medication Information
Daptomycin dose, administration date and time, order
discontinuation date and time
Vancomycin dose, administration date and time, order
discontinuation date and time
Dose, administration date and time, order discontinuation date and
time for other anti-infective agents
Aminoglycosides
Antifungals
Antituberculosis agents
Antiviral agents
Carbapenems
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999.32
996.61
996.63
996.64
996.65
996.68
996.69

Cephalosporins
Glycylcyclines
Leprostatics
Lincomycin derivatives
Macrolide derivatives
Miscellaneous antibiotics (aztreonam, colistimethate,
dalfopristin-quinupristin, linezolid, metronidazole, polymyxin
B)
Penicillins
Quinolones
Sulfamethoxazole/trimethoprim
Microbiology Results
Positive blood cultures
Daptomycin susceptibility
Oxacillin susceptibility
Vancomycin susceptibility
Susceptibility testing method
Laboratory Values
Creatine kinase
Serum creatinine
Vancomycin trough level
Clinical Outcomes
Echocardiogram performed
Infectious diseases service consultation
Cardiac source control procedures
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Operations on valves and septa of heart

35.xx

Other operations on heart and pericardium

37.xx

Skin/soft tissue source control procedures

See Appendix
B

Osteoarticular source control procedures

See Appendix
B

Hospital length of stay
Discharge status
Time to readmission
Date of death
Safety Outcomes
Rhabdomyolysis

728.88

Intestinal infection due to Clostridium difficile

008.45

ICD 9 - International Classification of Diseases, 9th Revision
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APPENDIX B
Current Procedural Terminology (CPT) Codes for Source Control Procedures Queried
from University of Kentucky HealthCare Enterprise Data Trust
Procedure

CPT Code Range

Incision and drainage procedures on the skin, subcutaneous,
and accessory structures

10040-10180

Debridement procedures on the skin

11000-11047

Biopsy procedures on the skin

11100-11101

Removal of skin tags procedures

11200-11201

Excision-benign lesions procedures on the skin

11400-11471

Excision-malignant lesions procedures on the skin

11600-11646

Skin replacement surgery

1500-15278

Pressure ulcers (decubitus ulcers) procedures
Local treatment procedures for burns

15920-15999
1600-16036

General introduction or removal procedures on the
musculoskeletal system

20500-20697

Excision procedures on the neck (soft tissues) and thorax

21550-21632

Repair, revision, and/or reconstruction procedures on the
neck (soft tissues) and thorax

21685-21750

Fracture and/or dislocation procedures on the neck (soft
tissues) and thorax

21805-21825

Excision procedures on the spine (vertebral column)

22100-22116

Osteotomy procedures on the spine (vertebral column)

22206-22226

Fracture and/or dislocation procedures on the spine
(vertebral column)

22305-22328

Arthrodesis procedures of the spine (vertebral column)

22532-22819
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Spinal instrumentation procedures on the spine (vertebral
column)

22840-22865

Incision procedures on the shoulder

23000-23044

Excision procedures on the shoulder

23065-23229

Introduction or removal procedures of the shoulder

23330-23350

Repair, revision, and/or reconstruction procedures on the
shoulder

23395-23491

Fracture and/or dislocation procedures on the shoulder

23500-23680

Arthrodesis procedures on the shoulder

23800-23802

Amputation procedures on the shoulder

23900-23921

Other procedures on the shoulder

23929-23929

Incision procedures on the humerus (upper arm) and elbow

23930-24006

Excision procedures on the humerus (upper arm) and elbow

24065-24115

Introduction or removal procedures on the humerus (upper
arm) and elbow

24160-24220

Repair, revision, and/or reconstruction procedures on the
humerus (upper arm) and elbow

24300-24498

Fracture and/or dislocation procedures on the humerus
(upper arm) and elbow

24500-24685

Arthrodesis procedures on the humerus (upper arm) and
elbow

24800-24802

Amputation procedures on the humerus (upper arm) and
elbow

24900-24940

Incision procedures on the forearm and wrist

25000-25040

Excision procedures on the forearm and wrist

25065-25240

Introduction or removal procedures on the forearm and wrist

25246-25259

Repair, revision, and/or reconstruction procedures on the
forearm and wrist

25260-25492
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Fracture and/or dislocation procedures on the forearm and
wrist

25500-25695

Arthrodesis procedures on the forearm and wrist

25800-25830

Amputation procedures on the forearm and wrist

25900-25931

Incision procedures on the hand and fingers

26010-26080

Excision procedures on the hand and fingers

26100-26262

Introduction and removal procedures on the hand and
fingers

26320-26320

Repair, revision, and/or reconstruction procedures on the
hand and fingers

26340-26596

Fracture and/or dislocation procedures on the hand and
fingers

26600-26785

Amputation procedures on the hand and fingers

26820-26863

Incision procedures on the pelvis and hip joint

26990-27036

Excision Incision procedures on the pelvis and hip joint

27040-27080

Introduction or removal Incision procedures on the pelvis
and hip joint

27086-27096

Repair, revision, and/or reconstruction Incision procedures
on the pelvis and hip joint

27097-27187

Fracture and/or dislocation Incision procedures on the pelvis
and hip joint

27193-27269

Manipulation procedures on the pelvis and hip joint

27275-27275

Arthrodesis procedures on the pelvis and hip joint

27279-27286

Amputation procedures on the pelvis and hip joint

27290-27295

Incision procedures on the femur (thigh region) and knee
joint

27301-27310

Excision procedures on the femur (thigh region) and knee
joint

27323-27365
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Repair, revision, and/or reconstruction procedures on the
femur (thigh region) and knee joint

27380-27499

Fracture and/or dislocation procedures on the femur (thigh
region) and knee joint

27500-27566

Manipulation procedures on the femur (thigh region) and
knee joint

27570-27570

Amputation procedures on the femur (thigh region) and
knee joint

27590-27598

Incision procedure on the leg (tibia and fibula) and ankle
joint

27600-27612

Excision procedure on the leg (tibia and fibula) and ankle
joint

27613-27647

Repair, revision, and/or reconstruction procedure on the leg
(tibia and fibula) and ankle joint

27650-27745

Arthrodesis procedure on the leg (tibia and fibula) and ankle
joint

27870-27871

Amputation procedure on the leg (tibia and fibula) and ankle
joint

27880-27889

Incision procedures on the foot and toes

28001-28035

Excision procedures on the foot and toes

28039-28175

Removal of foreign body procedures on the foot and toes

28190-28193

Repair, revision, and/or reconstruction procedures on the
foot and toes

28200-28360

Fracture and/or dislocation procedures on the foot and toes

28400-28675

Arthrodesis procedures on the foot and toes

28705-28760

Amputation procedures on the foot and toes

28800-28825
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APPENDIX C
Variable Definitions and Characteristics
Study Variable
Outcomes Variables
Treatment failure
(primary efficacy
outcome)

Dataset Variable

Definition

mort60 + readmit90 +
recur30

60-day mortality

cx_to_death, cul1,
DEATH_DT

90-day all-cause
readmission

DAYS_TO_READMIT

30-day recurrence of S.
aureus from blood
culture

cul1, cul2

A composite outcome where if
any of those conditions were
met, then considered a
treatment failure and fail=1
Determined by the number of
days between first positive
blood culture collection and
date of death. If missing, then
DEATH_DT=999. If <60 then
mort60=1
Days between encounters. If
missing, then
DAYS_TO_READMIT=999.
If <90 then readmit90=1
If days between collection of
1st positive culture and 2nd
positive culture after initial
clearance <30 then recur30=1
Diagnosis based on ICD-9
code, see Appendix A

Clostridium difficile
C_DIFF
infection (safety
outcome)
Rhabdomyolysis (safety RHABDOMYOLYSIS,
outcome)
HighCK,
Nephrotoxicity (safety
outcome)

Study Covariates
Gender
Race
Age
Charlson comorbidity
index
Admitted to intensive
care unit
History of intravenous
drug use

risk_cr + risk_crcl + inj_cr
+ inj_crcl + fail_cr +
fail_crcl

GENDR_CD

Diagnosis based on ICD-9
code, see Appendix A, creatine
kinase(CK) value >1500
A composite outcome where if
RIFLE criteria were met by
serum creatinine or creatinine
clearance definitions, then
nephrotoxicity=1

Derived gender available in
EDT
RACE_CD_DES
Derived race available in EDT
AGE
Derived age at time of
encounter available in EDT
COMORBIDITY_SCORE Derived severity of illness
score available in EDT
ADM2ICU
Derived from admission
location available in EDT
IV_DRUG
Diagnosis based on ICD-9
code, see Appendix A
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Cardiac prosthesis
Time to positive culture

CARDIAC_PROSTHESI
S
cul1, ADMT_DT

Time to clear blood
cultures

cul1, cul2

Methicillin-resistant S.
aureus
Vancomycin minimum
inhibitory concentration
(MIC)

OXA_SUSC, MRSA

Daptomycin MIC

DAP_S, DAPTMIC

E-test performed

MIC_Method

Length of stay

LOS

Source control achieved

bjsrccntrl, cardsrccntrl,
linesrccntrl,
source_control
D_DOT + V_DOT

Duration of therapy

Polymicrobial
bloodstream infection

Other infectious
organisms
Fungal organisms

VANMIC

polymicro_BSI,
gram_neg_BSI,
gram_pos_BSI,
fungal_BSI
other_orgs,
other_gram_neg,
other_gram_pos,
other_fungal,
non_urine_fungal, source,
species
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Diagnosis based on ICD-9
code, see Appendix A
Days between admission date
and first positive blood culture
Days between first positive
blood culture and last positive
blood culture
If OXA_SUSC=0 then
MRSA=1
Derived from vancomycin
MIC or susceptibility available
in EDT. If only reported as
susceptible, then VANMIC=1
Derived from daptomycin MIC
or susceptibility available in
EDT. If only reported as
susceptible, then
DAPTMIC=1. If only reported
as non-susceptible, then
DAPTMIC=1.5
Derived from susceptibility
testing method available in
EDT
Derived length of stay
available in EDT
Based on CPT codes, see
Appendix B
Sum of days of therapy of
daptomycin and day of therapy
of vancomycin
Indicates if another organism
grew in the same blood culture
as a S. aureus isolate
Indicates if another organism
grew from subsequent blood
cultures or other tissue samples
Indicates if a fungus grew from
subsequent blood cultures or
other tissue samples. Describes
site of fungal growth and
fungal species identified.
Fungi was determined to be a
urinary source if >100,000

Ceftaroline

CEFTRLN

Gentamicin

GENTMC

Rifampin

RIFMPN

TrimethoprimSulfamethoxazole

SMXTMP

Cefepime

CEFPM

Cefazolin

CEFZLN

Meropenem

MERPNM

Nafcillin

NAFCLLN

Piperacillin/Tazobacta
m

PIPTZB

Tobramycin or
Amikacin

Other_AG

Amphotericin
formulation

AMPHBLIP + ABLC

Daptomycin dose

dapto_mg, INIT_WT

Vancomycin trough

firstvanc_lvl2
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colony forming units of fungal
species grew from urine
culture with no concomitant
positive blood or nonpulmonary tissue sources
Indicates ceftaroline was
administered during the
encounter
Indicates gentamicin was
administered during the
encounter
Indicates rifampin was
administered during the
encounter
Indicates
trimethoprim/sulfamethoxazol
e was administered during the
encounter
Indicates cefepime was
administered during the
encounter
Indicates cefazolin was
administered during the
encounter
Indicates meropenem was
administered during the
encounter
Indicates nafcillin was
administered during the
encounter
Indicates
piperacillin/tazobactam was
administered during the
encounter
Indicates tobramycin or
amikacin was administered
during the encounter
Indicates an amphotericin B
formulation was administered
during the encounter
First daptomycin dose
administered divided by initial
weight. If INIT_WT missing,
then imputed as standard 70kg
First vancomycin trough serum
concentration collected

Baseline glomerular
filtration rate (GFR)

AGE, FIRST_CRVAL

Baseline creatine kinase baselineCK
(CK)
EDT=Enterprise Data Trust
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First GFR calculated using a
modified Cockcroft-Gault
equation
Derived from first CK value
available in EDT

APPENDIX D
Full Logistic Regression Model for Treatment Success Adjusting for Significant
Covariates

Odds Ratio
Estimate

95%
Confidence Interval

Pvalue

Group

1.043

0.581

1.873

0.8882

Time to positive culture, days

0.967

0.929

1.007

0.1081

Vancomycin MIC, mg/L

1.013

0.293

3.498

0.9839

Length of stay, days

1.023

0.994

1.053

0.1276

Ceftaroline

1.316

0.418

4.149

0.6389

Sulfamethoxazole/Trimethoprim

0.402

0.085

1.892

0.2487

Piperacillin/Tazobactam

1.112

0.468

2.642

0.8099

Tobramycin or Amikacin

2.219

0.514

9.572

0.2853

Amphotericin

0.385

0.074

1.999

0.2562

IV Drug Use

2.425

0.493

11.939

0.2761

Other Infectious Organisms

0.342

0.091

1.279

0.1108

Gram Negative Organisms

3.176

0.833

12.103

0.0905

Gram Positive Organisms

0.684

0.182

2.569

0.5742

Fungal Organisms from Non-Urinary
Source

1.213

0.205

7.173

0.8311
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